Blair William & Co. IL Has $172,000 Holdings in VistaGen Therapeutics, Inc. $VTGN

Blair William & Co. IL cut its holdings in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) by 14.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 85,866 shares of the company’s stock after selling 15,000 shares during the period. Blair William & Co. IL owned approximately 0.29% of VistaGen Therapeutics worth $172,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. ADAR1 Capital Management LLC grew its stake in shares of VistaGen Therapeutics by 246.4% in the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock valued at $1,052,000 after acquiring an additional 299,304 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics in the first quarter valued at about $25,000. Finally, Bank of America Corp DE grew its stake in shares of VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares in the last quarter. 78.39% of the stock is currently owned by institutional investors and hedge funds.

VistaGen Therapeutics Stock Performance

VTGN opened at $4.05 on Monday. The company’s 50 day moving average is $3.44 and its 200-day moving average is $2.74. VistaGen Therapeutics, Inc. has a 1-year low of $1.90 and a 1-year high of $4.39. The company has a market cap of $124.25 million, a P/E ratio of -2.28 and a beta of 0.55.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.47). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.22 million. On average, equities analysts forecast that VistaGen Therapeutics, Inc. will post -1.77 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, VistaGen Therapeutics presently has an average rating of “Hold”.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.